

## Corporate Profile

Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit [www.cipherpharma.com](http://www.cipherpharma.com).

## Stock Performance

CPH (Common Stock)

Exchange	TSX (Canadian Dollar)
Price	Can\$4.47
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	Can\$3.50
Market Cap	Can\$118,995,195
Rolling EPS	-1.47
PE Ratio	0
Shares Outstanding	26,620,849

Data as of 09/18/17 2:23 p.m. ET



## Recent Headlines & Events

06/02/17 - 7:00 a.m.

Cipher Pharmaceuticals Adds New Vice President of Corporate Development

05/12/17 - 10:35 a.m.

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders


05/11/17 - 7:06 a.m.

Cipher Pharmaceuticals Reports Q1 2017 Financial Results

There are currently no events scheduled.

## Analyst Estimates / Ratings

Mean Recommendation: 2.4



## EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Sep 17	0.14	0.14	0.10
QTR	Dec 17	0.12	0.12	0.07
QTR				
QTR				
FY	Dec 17	0.36	0.29	0.34
FY	Dec 18	0.45	0.52	0.51

## SEC Filings

Filing Date	Form
02/22/17	15-12B/A
01/17/17	15-12B
01/03/17	6-K
12/21/16	S-8 POS

## Corporate Governance

Shawn Patrick O'Brien	President & CEO
Norman Evans, CA	Chief Financial Officer
Ralph Boher	President & General Manager, United States
Joan Chypyha	President and General Manager, Canada
Brian Rosenberger	Vice President, Alliance and Strategic Portfolio Management
Linda Angaritis	Vice President, Global Regulatory Compliance and Quality
Lynne Bulger	VP Global Medical and Clinical Affairs
Peter Weiler	Vice President, Business Development
Mark Spina, CPA	Senior Vice President, Finance and Treasury

Chuck Jenkins

Vice President, Marketing,  
United States

Daniel B. Ward, Jr.,  
M.D., FAAD

Medical Director, United States

## Ownership Summary

### Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	24	48.56	49.8	13,243,845
Mutual Fund	14	14.28	15.4	4,103,487
Insider *	22	4.77	3.9	1,041,786

\*Insider values reflect direct beneficial ownership.

### Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Mull (John D M.D.)	9,751,265	36.6	-450,524	03/31/17
Grandeur Peak Global Advisors, LLC	1,941,100	7.3	-159,500	06/30/17
CHS Asset Management Inc.	571,104	2.2	571,104	06/30/17
1832 Asset Management L.P.	207,483	0.8	0	04/30/17
Claypool (William D)	164,048	0.6	1,527	07/15/16
SEI Investments Canada	130,856	0.5	0	03/31/17
Deboeck (Arthur Marie Joseph Ghislain)	102,800	0.4	102,800	03/31/17
McDole (Gerald P)	76,611	0.3	268	07/15/16
Wolkin (Harold M)	73,871	0.3	1,576	08/15/17
Beaudet (Mark A)	52,681	0.2	2,157	08/15/17

Data provided by Nasdaq. Minimum 15 minutes delayed.